IP finance

"Where money issues meet IP rights". This weblog looks at financial issues for intellectual property rights: securitisation and collateral, IP valuation for acquisition and balance sheet purposes, tax and R&D breaks, film and product finance, calculating quantum of damages--anything that happens where IP meets money.

Tuesday, 21 August 2018

Professor Nguyen on Sovereign Patent Funds

›
Professor Xuan-Thao Nguyen explores government created and funded patent funds in Sovereign Patent Funds recently published in the UC Davi...
Tuesday, 7 August 2018

The US Falling Behind on 5G Infrastructure: Lack of Funding and Slow Unified Policy Response?

›
Deloitte Consulting has released an informative report titled, “5G: The Chance to Lead for aDecade.” [Report]   The Report describes ho...
Saturday, 4 August 2018

Bloomberg Tracking Pharmaceutical Prices

›
One way the Trump Administration appears to attempt to control drug prices is through use of the “bully pulpit.”   Wikipedia states that...
Friday, 3 August 2018

The Merit of Patent Boxes

›
In a new paper on the merit of patent boxes, Should There Be Lower Taxes on Patent Income , Fabian Gaessler, Brownyn H. Hall and Dietmar...

Federal Funding for National Institutes of Health in the United States will likely Continue to Decline

›
The Trump Administration is seeking cuts to the budget of the National Institutes of Health (NIH) for Fiscal Year 2019.   In dollars adj...
Thursday, 26 July 2018

Facebook, Artifical Intelligence, IP and Universities

›
In a recent New York Times article, “Facebook Adds AI Labsin Seattle and Pittsburg, Pressuring Local Universities,” Cade Metz describes F...
Friday, 20 July 2018

New Trump Administration U.S. FDA Working Group on Importation of Pharmaceuticals

›
The U.S. Secretary of the Department of Health and Human Services, Alex Azar, has recently directed the Food and Drug Administration (FDA) C...

US Department of Energy Online Laboratory Partnering Service

›
The U.S. Department of Energy (DOE) has released a new Lab Partnering Service that allows review of patents for licensing from 17 national...
Thursday, 19 July 2018

Trump Administration FDA Moves to Speed Up Biosimilar Process in United States

›
The high cost of health care in the United States is a significant issue.  Some research points to two causes of the high cost in the United...
‹
›
Home
View web version
Powered by Blogger.